Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.580
-0.020 (-1.25%)
Mar 9, 2026, 1:34 PM EDT - Market open

Innate Pharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Market Capitalization
151166233282400334
Upgrade
Market Cap Growth
-23.07%-29.08%-17.19%-29.50%19.60%-36.34%
Upgrade
Enterprise Value
113107180196283177
Upgrade
Last Close Price
1.601.842.803.734.564.09
Upgrade
PS Ratio
10.187.953.434.5814.243.92
Upgrade
PB Ratio
25.0118.114.074.873.271.75
Upgrade
P/TBV Ratio
25.0118.114.105.025.562.49
Upgrade
EV/Sales Ratio
7.605.152.653.1910.072.07
Upgrade
EV/EBITDA Ratio
-----10.86
Upgrade
EV/EBIT Ratio
-----133.87
Upgrade
Debt / Equity Ratio
5.253.510.770.780.410.12
Upgrade
Debt / EBITDA Ratio
-----1.33
Upgrade
Net Debt / Equity Ratio
-6.41-5.63-1.01-1.09-0.70-0.85
Upgrade
Net Debt / EBITDA Ratio
0.660.996.164.931.75-9.96
Upgrade
Net Debt / FCF Ratio
0.806.831.603.011.272.52
Upgrade
Asset Turnover
0.100.140.330.250.090.20
Upgrade
Quick Ratio
2.082.503.513.211.673.64
Upgrade
Current Ratio
2.212.603.733.381.733.81
Upgrade
Return on Equity (ROE)
-271.37%-162.91%-14.28%-71.75%-34.53%-0.44%
Upgrade
Return on Assets (ROA)
-25.92%-22.52%-4.23%-4.40%-10.40%0.19%
Upgrade
Return on Invested Capital (ROIC)
----122.70%-173.03%5.30%
Upgrade
Return on Capital Employed (ROCE)
-79.80%-66.10%-9.30%-10.40%-25.50%0.40%
Upgrade
Earnings Yield
-35.79%-30.93%-3.58%-22.02%-15.02%-23.41%
Upgrade
FCF Yield
-31.55%-4.56%-15.58%-7.46%-16.89%-19.27%
Upgrade
Buyback Yield / Dilution
-4.15%-0.74%-1.02%-0.12%-0.77%-17.97%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.